Eli Lilly and Company (LLY)

NYQ – Real Time Price. Currency in USD

878.24

-18.76 (-2.09%)

At close: Mar 27, 2026, 4:00 PM EDT

874.72

-3.52 (-0.40%)

After-hours: Mar 27, 2026, 7:59 PM EDT

About the company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Key Executives

Name	Position
Dr. Daniel M. Skovronsky M.D., Ph.D.	Chief Scientific & Product Officer and President of Lilly Research Laboratories
Dr. Ruth Gimeno Ph.D.	Group Vice President, Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development
Kim Macko	Senior Director of R&D Strategy and Transformation
Mr. David A. Ricks	Chairman & CEO
Mr. Jacob S. Van Naarden	Executive VP & President of Lilly Oncology
Mr. Kevin Hern	Vice President of Investor Relations
Mr. Lucas E. Montarce	Executive VP & CFO